Premium
THE EFFECT OF MISOPROSTOL ON COLON CANCER
Author(s) -
Lawson Jane A.,
Adams Warwick J.,
Morris David L.
Publication year - 1994
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1994.tb02178.x
Subject(s) - misoprostol , medicine , prostaglandin e1 , in vivo , colorectal cancer , oral administration , prostaglandin , prostaglandin analogue , cancer , gastroenterology , pharmacology , pregnancy , abortion , genetics , microbiology and biotechnology , biology
A synthetic prostaglandin E 1 (PGE 1 ) analogue, misoprostol, was investigated for its effects on the growth of colon cancer in two in vivo models. Human colon cancer cell lines C170, LIM2412 and LIM2405 were grown as subcutaneous xenografts on T‐lymphocyte deficient ARC(s) nu/nu mice. Tumour volumes were found to be significantly inhibited compared with control in misoprostol‐treated animals with two cell lines. C170 was inhibited by 70.5% ( P = 0.001) and LIM2412 by 68.2% ( P = 0.01). LIM2405 was inhibited by 33% ( P = 0.14) which was not significantly different from the control. In a second experiment, colon cancers were induced in Sprague‐Dawley rats using 1,2 dimethyl‐hydrazine (DMH). After 10 weeks of treatment, rats were randomized to receive a 5 week course of 20 μg/kg per day of oral misoprostol. Misoprostol‐treated rats were found to have a similar tumour incidence and staging compared with control animals. Oral administration of misoprostol has an inhibitory effect on early tumour growth of some colonic cancers, but not on established tumours.